Denosumab as an add-on Neoadjuvant Treatment (GeparX)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

780 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-13

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.

In a retrospective analysis it could be demonstrated that elevated expression of RANK was found in 14.5% of patients overall, with a significant predominance in patients with hormone-receptor-negative disease. Expression of RANK was associated with a higher pathological complete response rate but with a shorter disease-free and overall survival. The ABCSG-18 study showed that adjuvant denosumab reduces clinical fractures, improves bone health, and can be administered without added toxicity.

It appears therefore reasonable to test denosumab, a clinically available antibody against RANKL in patients with hormone-receptor-negative primary breast cancer as an adjunct to neoadjuvant chemotherapy for its ability to increase pCR rate and improve outcome in relation to the expression of RANK.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823

Breast Cancer

ACTIVE_NOT_RECRUITING PHASE3

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel

NCT02073487

Breast Cancer

COMPLETED PHASE2

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

NCT00006123

Breast Cancer

WITHDRAWN PHASE1/PHASE2

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

NCT02125344

Tubular Breast Cancer Stage II Tubular Breast Cancer Stage III Mucinous Breast Cancer Stage II +4 more

COMPLETED PHASE3

Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer

NCT03532087

Breast Neoplasms

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

RANK ligand (RANKL), a key factor for bone remodeling and metastasis, is crucial for the development of mouse mammary glands during pregnancy. RANKL functions as a major paracrine effector of the mitogenic action of progesterone in mouse and human mammary epithelium via its receptor RANK and has a role in ovarian hormone-dependent expansion and regenerative potential of mammary stem cells. Pharmacologic inhibition of RANKL attenuates the development of mammary carcinoma and inhibits metastatic progression in multiple mouse models.

In a retrospective analysis of 601 patients treated in the GeparTrio study with chemotherapy (TAC) it could be demonstrated that elevated expression of RANK (immunohistochemical score \> 8.5 using the N-1H8 antibody by Amgen) was found in 14.5% of patients overall, with a significant predominance in patients with hormone-receptor-negative disease (33.7% vs 6.4% tumors positive for RANK). Expression of RANK was associated with a higher pathological complete response rate (pCR) (23.0% vs 12.6%) but with a shorter disease-free and overall survival. The ABCSG-18 study showed that adjuvant denosumab reduces clinical fractures, improves bone health, and can be administered without added toxicity. Moreover denosumab improves disease-free survival in postmenopausal woman with hormone receptor positive breast cancer.

It appears therefore reasonable to test denosumab, a clinically available antibody against RANKL in patients with hormone-receptor-negative primary breast cancer as an adjunct to neoadjuvant chemotherapy for its ability to increase pCR rate and improve outcome in relation to the expression of RANK.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer Female NOS Tubular Breast Cancer Stage II Mucinous Breast Cancer Stage II Invasive Ductal Breast Cancer HER2 Positive Breast Cancer Inflammatory Breast Cancer Tubular Breast Cancer Stage III

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Denosumab

Denosumab every 4 weeks for 6 cycles.

Group Type EXPERIMENTAL

Denosumab

Intervention Type DRUG

Denosumab 120 mg every 4 weeks for 6 cycles

nab-Paclitaxel weekly

nab-Paclitaxel weekly for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin in parallel to nab-paclitaxel.

Group Type EXPERIMENTAL

nab-Paclitaxel

Intervention Type DRUG

nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)

Carboplatin

Intervention Type DRUG

Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel

Trastuzumab

Intervention Type DRUG

Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Pertuzumab

Intervention Type DRUG

Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles

nab-paclitaxel 2 of 3 weeks

nab-Paclitaxel day 1,8 q22 for 12 weeks. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab. Patients with triple-negative tumors receive Carboplatin weekly in parallel to nab-paclitaxel.

Group Type EXPERIMENTAL

nab-Paclitaxel

Intervention Type DRUG

nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)

Carboplatin

Intervention Type DRUG

Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel

Trastuzumab

Intervention Type DRUG

Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Pertuzumab

Intervention Type DRUG

Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles

EC every two weeks or every three weeks

Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.

Group Type EXPERIMENTAL

Epirubicin

Intervention Type DRUG

Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times

Cyclophosphamide

Intervention Type DRUG

Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times

Trastuzumab

Intervention Type DRUG

Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Pertuzumab

Intervention Type DRUG

Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Denosumab

Denosumab 120 mg every 4 weeks for 6 cycles

Intervention Type DRUG

nab-Paclitaxel

nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)

Intervention Type DRUG

Epirubicin

Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times

Intervention Type DRUG

Cyclophosphamide

Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times

Intervention Type DRUG

Carboplatin

Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel

Intervention Type DRUG

Trastuzumab

Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles

Intervention Type DRUG

Pertuzumab

Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Human monoclonal IgG2 antibody Abraxane Farmorubicin Endoxan Diamminplatin(II)-cyclobutan-1,1-dicarboxylat Herceptin Perjeta

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration from the breast lesion alone is not sufficient. Incisional biopsy or axillary clearance is not allowed. In case of bilateral cancer, the investigator has to decide prospectively which side will be evaluated for the primary endpoint.
* Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter. The lesion has to be measurable in two dimensions, preferably by sonography. In case tumor isn't measurable by sonography, then MRI or mammography is sufficient. In case of inflammatory disease, the extent of inflammation can be used as measurable lesion.
* Patients must have stage cT1c - cT4a-d disease.
* In patients with multifocal or multicentric breast cancer, the largest lesion should be measured.
* Centrally confirmed ER-negative and PR-negative status. Central pathology includes also assessment of HER2, Ki-67, TIL and RANK status on core biopsy. ER/PR negative is defined as ≤1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridization (ISH) and according to ASCO-CAP guidelines as of 2013. LPBC (lymphocyte predominant breast cancer) is defined as more than 50% stromal tumour infiltrating lymphocytes. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization.

Exclusion Criteria

* Patients with stages cT1a, cT1b, or any M1.
* Prior chemotherapy for any malignancy.
* Prior radiation therapy for breast cancer.
* History of disease with influence on bone metabolism, such as osteoporosis, Paget's disease of bone, primary hyperparathyroidism requiring treatment at the time of randomization or considered likely to become necessary within the subsequent six months.
* Use of bisphosphonates or denosumab within the past 1 year.
* Significant dental/oral disease, including prior history or current evidence of osteonecrosis/ osteomyelitis of the jaw, active dental or jaw condition which requires oral surgery, non-healed dental/oral surgery, planned invasive dental procedure for the course of the study.
* Previous malignant disease being disease-free for less than 5 years (except CIS of the cervix and non-melanomatous skin cancer).
* Known or suspected congestive heart failure (\>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP \>140 / 90 mm Hg under treatment with two antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
* Currently active infection.
* Incomplete wound healing.
* Definite contraindications for the use of corticosteroids.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No